The in vivo study of inflammasome NOD-like receptor protein 3 (NLRP3) as a starting point for the development of new innovative migraine drugs
Michela Argentieri, Simona Stragapede, Chiara Sturaro, Pietro Pola, Valentina Albanese, Salvatore Pacifico, Delia Preti, Carlotta Giorgi, Sonia Missiroli, Chiara Ruzza · FENS Forum 2024
Migraine is a recurrent headache disorder characterized by episodes of acute pain. The overall objective of this work, was to test the hypothesis that the NLRP3 inflammasome is involved in the pathophysiology of migraine and that NLRP3 blockade may represent a novel strategy for migraine management through the design of novel inhibitors. The phenotype of NLRP3 knockout (NLRP3 KO) mice has been investigated in a mouse model of migraine induced by the i.p. administration of nitroglycerin (NTG). Using the same model, were tested the effects of MCC950, a standard NLRP3 inhibitor able to cross the